Inhibrx (INBX) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INBX shares.
View INBX analyst ratings or view top-rated stocks.

4 brokerages have issued 12 month price targets for Inhibrx's shares. Their INBX share price forecasts range from $27.00 to $60.00. On average, they predict the company's stock price to reach $44.33 in the next twelve months. This suggests a possible upside of 127.6% from the stock's current price.
View analysts price targets for INBX or view top-rated stocks among Wall Street analysts.

Inhibrx's stock was trading at $24.64 at the beginning of the year. Since then, INBX stock has decreased by 20.9% and is now trading at $19.48.
View the best growth stocks for 2023 here.

Inhibrx saw a decline in short interest in August. As of August 31st, there was short interest totaling 5,090,000 shares, a decline of 12.8% from the August 15th total of 5,840,000 shares. Based on an average trading volume of 398,300 shares, the days-to-cover ratio is presently 12.8 days. Approximately 15.3% of the shares of the stock are sold short.
View Inhibrx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our INBX earnings forecast.

Inhibrx, Inc. (NASDAQ:INBX) released its quarterly earnings results on Monday, August, 7th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by $0.06. The company had revenue of $0.03 million for the quarter. Inhibrx had a negative net margin of 28,749.25% and a negative trailing twelve-month return on equity of 5,168.31%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

(INBX) raised $102 million in an initial public offering on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Inhibrx trades on the NASDAQ under the ticker symbol "INBX."

Inhibrx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (8.30%), BlackRock Inc. (5.83%), State Street Corp (4.16%), Woodline Partners LP (3.49%), ArrowMark Colorado Holdings LLC (2.20%) and Geode Capital Management LLC (1.51%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends.

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INBX stock can currently be purchased for approximately $19.48.

Inhibrx (NASDAQ:INBX) has a market capitalization of $850.69 million and generates $2.19 million in revenue each year. The company earns $-145,230,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis.

The company employs 132 workers across the globe.

Inhibrx's mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The official website for the company is www.inhibrx.com. The company can be reached via phone at 858-795-4220 or via email at amy@juniper-point.com.